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Disclosures
The author of this presentation has no
relevant financial or non-financial
relationships in the products described
and reviewed in this presentation.

Objectives


Review the scope and purpose of USP
<797> and USP <800> and identify key
differences between the two chapters



Describe proposed changes to USP <797>
and USP <800> as well as timelines for
implementation



Identify challenges that pharmacies may
face in implementing the new standards

USP <797> Scope


Applies to compounded sterile preparations
in all settings



Describes conditions and practices to
prevent harm from:

Microbial contamination (non-sterility)
 Excessive bacterial endotoxins
 Variability in the intended strength of
ingredients
 Unintended physical and chemical
contaminants
 Ingredients of inappropriate quality in
compounded sterile products (CSPs)
USP General Chapter <797> Pharmaceutical Compounding—Sterile Preparations. 2008.


USP <797> Proposed
Major Changes
2008 Version

Proposed 2019 Update

Three risk levels for CSPs
• Low risk: aseptic manipulations
within ISO 5 or better hoods;
combining 3 or less sterile
products into a single bag/vial
• Medium risk: combining > 3
commercial sterile drug products
and those requiring complex
manipulations
• High risk: non-sterile
ingredients, lack effective
antimicrobial preservatives,
sterile surfaces

Simplified compounded sterile
preparation (CSP) microbial risk
levels
• Category 1 CSPs: shorter
beyond-use date (BUD), may be
prepared in an unclassified
segregated compounding area
(SCA)
• Category 2 CSPs: longer BUD,
must be prepared in a cleanroom
suite (buffer room with anteroom)

N/A

Guidance on use of opened or
punctured manufactured products
and CSPs

USP General Chapter <797> Pharmaceutical Compounding—Sterile Preparations. 2008.
https://www.usp.org/sites/default/files/usp/document/our-work/compounding/proposed-revisions-gc-797.pdf

USP <797> Proposed
Major Changes
2008 Version

Proposed 2019 Update

Section on “readying for
administration”

Scope of chapter excludes
administration of medications

Investigation in the event of:

Emphasis on conducting investigations
and implementing corrective actions in
specific situations such as:

•Sterility test failure
•Recovery of colony-forming units
during environmental monitoring

Radiopharmaceuticals as CSPs

•Media fill failure
•Personnel qualification failure
•Facility certification failure
•Out-of-specification results on lab tests
•Quality-control check failures
•Complaints indicating CSP quality issue
•Adverse events

Removal of section on
radiopharmaceuticals – Refer to General
Chapter <825>

USP General Chapter <797> Pharmaceutical Compounding—Sterile Preparations. 2008.
https://www.usp.org/sites/default/files/usp/document/our-work/compounding/proposed-revisions-gc-797.pdf

USP <797> Proposed
Major Changes
2008 Version
• Anti-neoplastics shall not be
prepared as immediate-use CSPs
• All personnel who compound
hazardous drugs shall be fully
trained in the storage, handling,
and disposal of these drugs –
annual verification

Proposed 2019 Update
Removal of information
related to handling of
hazardous drugs –Refer to
General Chapter <800>

• Storage preferably within a
containment area such as a
negative pressure
• Facilities that prepare a “low
volume” of HDs may compound in
a non-negative pressure room
with “two tiers of containment”
USP General Chapter <797> Pharmaceutical Compounding—Sterile Preparations. 2008.
https://www.usp.org/sites/default/files/usp/document/our-work/compounding/proposed-revisions-gc-797.pdf

USP <800> Scope


Purpose:


Describe practice and quality standards for
handling hazardous drugs in healthcare
settings and help promote patient safety,
worker safety, and environmental protection



Applies to all healthcare personnel who
handle HD preparations and all entities
that store, prepare, transport, or
administer HDs



Applies to both sterile and nonsterile
products

USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

Who is at Risk?

http://www.usp.org/sites/default/files/usp/document/our-work/healthcare-quality-safety/800-know-your-exposure-to-hazardous-drugs.pdf

Hazardous Drug Definitions
NIOSH

ASHP

Carcinogenicity

Carcinogenicity in animal models, in the
patient population, or in both

Teratogenicity or
developmental toxicity

Teratogenicity in animal studies or in
treated patients

Reproductive toxicity

Fertility impairment in animal studies or in
treated patients

Organ toxicity at low doses

Evidence of serious organ or other toxicity
at low doses in animal models or in treated
patients

Genotoxicity

Genotoxicity (i.e., mutagenicity and
clastogenicity in short-term test systems)

Structure and toxicity
profile of new drugs that
mimic existing drugs
determined by hazardous
criteria above
Power LA, Coyne JW. ASHP Guidelines on Handling Hazardous Drugs. Am J Health-Syst Pharm Oct 2018.

History of Hazardous
Drug Guidance


1983-84 - ASHP Practice Spotlight: safe
handling of cytotoxic drugs



2004 - NIOSH Alert



2006 - ASHP Guidelines on Handling Hazardous
Drugs



2008 - USP 797 revision in 2008 to harmonize
with NIOSH 2004 alert



2010 - NIOSH list of antineoplastic and
hazardous drugs



2016 - USP Chapter 800 Hazardous Drugs—
Handling in Healthcare Settings

NIOSH List
 National

Institute for Occupational
Safety and Health

3





groups of drugs:
Group 1: Antineoplastic drugs
Group 2: Non-antineoplastic drugs that
meet one or more of the NIOSH criteria for
a hazardous drug
Group 3: Reproductive risk

 Updated

every 2 years

NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016.

Hazardous Drugs List


Institution-specific HD list must be
maintained and reviewed annually



Assessment of new drugs



Classify investigational agents based on
mechanism of action



Re-categorization as new toxicologic
information becomes available



Consider dosage form

USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

Exposure Risk Points

http://www.usp.org/sites/default/files/usp/document/our-work/healthcare-quality-safety/800-know-your-exposure-to-hazardous-drugs.pdf

HD Receipt
 Receive

HD in sealed, impervious
plastic wrap

 Handle

with chemotherapy gloves

 Open

in neutral or negative-pressure
non-sterile area

 Immediately

deliver to
HD storage area

USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

HD Storage


HDs must be stored in an externally
ventilated, negative-pressure room with at
least 12 air changes per hour (ACPH)



Designated hazardous drug sign displayed



Restricted access



Antineoplastic HD requiring further
manipulation stored separately




Dedicated storage refrigerator

Sterile and non-sterile HD can be stored
together

USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

HD Sterile Compounding


Containment Primary Engineering Control
(C-PEC)




Externally vented
ISO Class 5 or better air quality
Biological safety cabinet (BSC)
• Class II
• Lined with plastic-backed mat



Compounding Aseptic Containment Isolator (CACI)

USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

Biological safety cabinet (BSC) II

HD Sterile Compounding


Containment Secondary Engineering
Control (C-SEC)





Externally vented
ISO Class 7 or better air quality
Negative pressure
HEPA filter
• 12 or 30 ACPH

USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

HD Sterile Compounding


Closed-System Transfer Devices (CSTD)

HD Non-sterile
Compounding


Containment Primary Engineering Control
(C-PEC)
 Externally vented or redundant HEPA filtered
 Biological safety cabinet (BSC) class I or II
 CACI
 Containment ventilated enclosure (CVE)



Containment Secondary
Engineering Control (C-SEC)
 Externally vented
 Negative pressure
 HEPA filter - 12 ACPH

USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

Environmental Quality
and Control


Environmental wipe studies for HDs should
be performed routinely at least every 6
months



Surface wipe sampling should include:






C‐PEC and equipment
Staging or work areas near
C‐PEC/pass‐through
Areas adjacent to C-PECs (floors)
Areas outside of buffer room and patient
administration areas

USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

Personal Protective
Equipment (PPE)


Protection, reduce exposure to HDs
aerosolization and drug residue



Handling all HDs: gloves



Compounding HDs: gowns, gloves, head,
hair, and double shoe covers




Double gloves for sterile compounding

Administering injectable HDs: gloves and
gowns

USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

Personal Protective
Equipment (PPE)


Spills, cleaning under C-PEC work surface,
suspected airborne HD exposure:




Chemical cartridge type respirator or powered
air-purifying respirator (PAPR)

Other activities requiring respiratory
protection:



N95 respirator
No protection vs. gases/vapors and little
protection vs. direct liquid splashes

USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

Hazard Communication Plan


Institutions must establish policies and
procedures for all aspects of HD handling



Elements of the plan:








Written plan on how the standard will be implemented
All containers of hazardous chemicals shall be labeled,
tagged, or marked with identity of the material and
appropriate hazard warnings
Safety Data Sheets (SDS) must be maintained for all
hazardous chemical used and accessible to staff
Training program for staff with potential for exposure
Personnel of reproductive capability confirm in writing
that they understand risks of handling HDs

USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

Personnel Training


Training prior to employee independently
handling HDs and reassessed annually



Must include:







Overview of the institution’s list of HDs
Review of SOPs related to handling of HDs
Proper use of PPE and equipment/devices
Spill management
Response to known or suspected HD exposure
Proper disposal of HDs

USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

Labeling/Packaging/Transp
ort


Labeling: HDs must be labeled as such



Packaging: Use containers to maintain
physical integrity, stability and sterility
during transport



Transport:




Use containers that minimize the
risk of breakage/leakage
Never use pneumatic tubes
to transport antineoplastic HDs

USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

HD Dispensing


HDs not requiring further manipulation
may be dispensed without further
requirements for containment, unless:





Required by manufacturer
Visual indicators of HD exposure

Segregate equipment used for dispensing
activities for HD

USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

HD Administration


HDs must be administered safely using
protective medical devices and techniques



Appropriate PPE worn when administering
HDs and disposed properly



CSTDs must be used for administration of
antineoplastic HDs when dosage form allows



Avoid manipulating HD dosage forms when
possible

USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

Deactivating, Decontaminating,
Cleaning, Disinfecting
Process

Description

Agents

Deactivation

Inactivation of
HD compounds

Sodium hypochlorite
(Bleach)
Peroxide

Decontamination

Physically
remove
inactivated
particles

Sodium hypochlorite
(Bleach)
Peroxide
Alcohol
Water

Cleaning

Removal of
organic/inorganic
material

Germicidal detergent

Disinfection

Inhibit/destroy
microorganisms

Sterile alcohol
Disinfectant

USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

HD Spills


Training about proper spill kit use



SOPs required for spill prevention and
cleanup procedures (including use of PPE
and respirators)



Document circumstances of spill



Immediate medical evaluation
for potentially exposed
personnel



Non‐employees exposed
should report to ED for evaluation

USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

HD Disposal


Bulk Hazardous Drug Waste





Trace‐Contaminated Waste






>3% of the capacity of the container
Chemotherapy vials (empty or partially full),
syringes, materials used to clean
Minimal drug (<3% total capacity)
Gowns, gloves, gauze, masks
May be incinerated at medical
regulated waste facility

Sharps


Needles, ampules, syringes

USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

Medical Surveillance
Program
 Should








have the following elements:

Baseline assessment of worker’s health
and medical history
Estimate of workers HD exposure over
time
Monitoring of organ function at risk for
toxicity from HD exposure
Follow‐up plan for acute and long‐term
exposure to HDs

USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

Old vs. New HD Standards
2008 Version USP <797>

Storage preferably within a
containment area such as a
negative pressure

USP <800>

HDs must be stored in an
externally ventilated, negativepressure room with at least 12 air
changes per hour (ACPH)
All facilities that prepare HDs must
have a containment secondary
engineering control (C-SEC)

Facilities that prepare a “low
volume” of HDs may
compound in a non-negative •Must be externally vented, physically
pressure room with “two tiers separated, have appropriate air
of containment”
exchange, and have a negative
pressure

USP General Chapter <797> Pharmaceutical Compounding—Sterile Preparations. 2008.
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

Old vs. New HD Standards
2008 Version USP <797>

Only allows low-risk non-HD
Compounded Sterile
Preparations (CSPs) with 12
hour or less beyond-use date
(BUD) to be prepared in an
unclassified segregated
compounding area (SCA)

USP <800>

Allows low and medium risk HD
CSPs to be prepared in an
unclassified containment
segregated compounding area
(C-SCA)
• C-SCA required to have fixed
walls, be externally vented with
30 ACPH and have negative
pressure

*Note differences in terminology and requirements in the
SCA in USP <797> and C-SCA in <800>
USP General Chapter <797> Pharmaceutical Compounding—Sterile Preparations. 2008.
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

USP Timeline for General
Chapter Revisions

Potential Challenges
 Financial/physical







plant

New equipment
Facility design changes
Separation of hazardous/non-hazardous
compounding
Storage

 Time



Documentation
More frequent environmental sampling

Potential Challenges
 Staff

training/education

 Lack

of evidence



Recommendations based on expert
panel opinions

 Impact


on low volume sites

Outpatient clinics, physician offices, etc.

2017 USP 797 Compliance Study

Douglass K, Kastango E, Cantor P. Pharmacy Purchasing and Products. 2017;14(10):16.

2017 USP 797 Compliance Study

Douglass K, Kastango E, Cantor P. Pharmacy Purchasing and Products. 2017;14(10):16.

2017 USP 797 Compliance Study

Douglass K, Kastango E, Cantor P. Pharmacy Purchasing and Products. 2017;14(10):16.

2017 USP 797 Compliance Study

Douglass K, Kastango E, Cantor P. Pharmacy Purchasing and Products. 2017;14(10):16.

2017 USP 797 Compliance Study

Douglass K, Kastango E, Cantor P. Pharmacy Purchasing and Products. 2017;14(10):16.

Self-Assessment


True/False: USP <800> applies only to
the compounding of sterile hazardous
drugs



True/False: USP <797> and USP <800>
updates are anticipated to become official
on December 1, 2019



True/False: The most common challenge
to achieving USP compliance has been
identified to be financial restrictions

Summary
 USP

797 sets sterile compounding
standards vs. USP 800 sets hazardous
drug handling standards

 Updated

versions will be enforceable
December 1, 2019

 Institutions

should determine
readiness to meet standards early

 Some

standards will require
significant investment of time and
money
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